Description | Macitentanisanorallyactive,non-peptidedualendothelinETAandETBreceptorantagonistforthepotentialtreatmentofidiopathicpulmonaryfibrosis(IPF)andpulmonaryarterialhypertension(PAH). |
---|---|
InVitro | TubeformationABIlityisrestoredwhenmicrovascularendothelialcellsarepreincubatedwithBOSormacitentan,alsoreducingtheexpressionofmesenchymalMarkersandrestoringCD31expressionandtheimbalancebetweenVEGF-AandVEGF-A165b[1].MacitentaninhibitsOATP1B1-mediateduptakeofatorvastatinandOATP1B3-mediateduptakeofestrone-3-sulfatewithIC50 ± SEvaluesof6.3 ± 0.7and11.8 ± 5.0 μM,respectively[3].TreatmentwithmacitentanorwithACT-132577doesnotleadtointracellularaccumulationofR123inHeyA8-MDR,showingthatthesecompoundsarenotP-gpinhibitors[4]. |
InVivo | Macitentan(25mg/kg/day,p.o.)preventsincreasedproductionofvasoactiveandfibrogenicfactors,NF-κBactivation,structuralandfunctionalchanges,andincreasesextracellularmatrixproteinproductionintype2diabetesintype2diabetes[2].Macitentan(10mg/kg,p.o.)coupledwithonce-per-week5mg/kgtaxol,significantlyreducestheweight(size)ofHeyA8-MDRtumorsinmice.Combinationtherapywithmacitentan(10or50mg/kg,butnot5mg/kg)andtaxolormacitentan(10mg/kg)andcisplatinumsignificantlyreducesthenumberofproliferatingKi-67-positivecells[4]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AnimalAdministration [2] | Macitentanispreparedinfoodadmix. Maledb/dbmiceandageandsex-matchedcontrols(27-32 g)areusedfortheassay.RandomLyselecteddiabeticanimalsaremonitoredforeither2 monthsorfor4 monthsafteronsetofdiabetes.Groups(n=7/group)ofthediabeticmicearesubjectedtooralmacitentantreatmentforthesameperiod(25 mg/kg/day,foodadmix).Theanimalsaremonitoredthroughassessmentofbodyweightandbloodglucose.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
References |
|
MolecularWeight | 588.27 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₁₉H₂₀Br₂N₆O₄S | ||||||||||||
CASNo. | 441798-33-0 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | 10mMinDMSO *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.95% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|